Utility of combined inflammatory biomarkers for the identification of cognitive dysfunction in non-diabetic participants of the ELSA-Brasil

Imagem de Miniatura
Arquivos
art_CEZARETTO_Utility_of_combined_inflammatory_biomarkers_for_the_identification_2019.PDF (255.21 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
CEZARETTO, Adriana
ALMEIDA-PITITTO, Bianca de
ALENCAR, Gizelton Pereira
FERREIRA, Sandra R. G.
AQUINO, Estela M. L.
MOTA, Eduardo L. A.
BARRETO, Sandhi Maria
Citação
PSYCHONEUROENDOCRINOLOGY, v.103, p.61-66, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Insulin resistance and low-grade inflammation are pathophysiological mechanisms shared by type 2 diabetes and dementia. A cluster of biomarkers that could help diagnosing cognitive dysfunction prior to the installation of insulin resistance is desirable. This ELSA sub-study examined whether a cluster of selected inflammatory biomarkers was associated with worse cognitive scores in non-diabetic participants. Methods: A sample of 998 non-diabetic participants of ELSA-Brasil had their cognitive function assessed by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), a verbal fluency test and a trail making test. An inflammatory cluster was formed by using the k-means method. ANOVA was used to compare the tertiles of a composite global cognitive z-score with clinical and laboratory variables. Logistic regression modelling with forward stepwise model selection was performed considering cognitive performance as the outcome and the cluster as the independent variable of main interest. Models were stratified by sex and adjusted for age, insulin resistance and other confounders. Results: The mean age was 45.7 +/- 4.9 years and 54.8% were women, who had a higher frequency of university level, healthier behaviors and lower systolic and diastolic blood pressure (BP) levels, fasting plasma glucose, non-HDL cholesterol and E-selectin levels than men. Individuals in the highest tertile of the composite global cognitive z-score were more likely to be women, with university level, and lower mean values of body mass index, BP levels, and HOMA-IR than those in lower tertiles. Using logistic regression model, the cluster category of the highest grade of inflammation showed to be associated with worse cognitive performance in women only. Conclusion: The association between a cluster of inflammation and worse cognitive performance seems to be useful to identify middle-aged women at risk for cognitive decline, independently of their state of insulin resistance.
Palavras-chave
Cognitive function, Prediabetes, Subclinical inflammation, Cluster analysis, Dementia, Prevention
URI
https://observatorio.fm.usp.br/handle/OPI/32411
Referências
  1. Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
  2. Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
  3. Almeida-Pititto B, 2015, DIABETES RES CLIN PR, V109, P110, DOI 10.1016/j.diabres.2015.04.021
  4. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  5. Au B, 2017, AGEING RES REV, V35, P176, DOI 10.1016/j.arr.2016.09.005
  6. Awad N, 2004, J CLIN EXP NEUROPSYC, V26, P1044, DOI 10.1080/13803390490514875
  7. Cezaretto A, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0354-1
  8. Chakrabarty P, 2015, NEURON, V85, P519, DOI 10.1016/j.neuron.2014.11.020
  9. Chatterjee S, 2016, DIABETES CARE, V39, P300, DOI 10.2337/dc15-1588
  10. de Almeida-Pititto B, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0133-9
  11. Passos VMD, 2011, ARQ NEURO-PSIQUIAT, V69, P814, DOI 10.1590/S0004-282X2011000600017
  12. Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890
  13. Farfel JM, 2013, NEUROLOGY, V81, P650, DOI 10.1212/WNL.0b013e3182a08f1b
  14. Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
  15. Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5
  16. Fraley C, 1998, COMPUT J, V41, P578, DOI 10.1093/comjnl/41.8.578
  17. Geloneze B, 2009, ARQ BRAS ENDOCRINOL, V53, P281, DOI 10.1590/S0004-27302009000200020
  18. Gerstorf D, 2006, J GERONTOL B-PSYCHOL, V61, pP245, DOI 10.1093/geronb/61.4.P245
  19. Gimeno D, 2008, PSYCHONEUROENDOCRINO, V33, P1322, DOI 10.1016/j.psyneuen.2008.07.006
  20. Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x
  21. Guillot-Sestier MV, 2015, NEURON, V85, P534, DOI 10.1016/j.neuron.2014.12.068
  22. Hallal PC, 2004, MED SCI SPORT EXER, V36, P556, DOI 10.1249/01.MSS.0000117161.66394.07
  23. Henderson VW, 2012, NEUROLOGY, V79, P1840, DOI 10.1212/WNL.0b013e318271f88f
  24. Hennessy E, 2017, BRAIN BEHAV IMMUN, V59, P233, DOI 10.1016/j.bbi.2016.09.011
  25. Hughes CG, 2018, INTENS CARE MED, V44, P345, DOI 10.1007/s00134-018-5120-1
  26. INZUCCHI S, 2010, DIABETES CARE S1, V33, pS62, DOI 10.2337/DC10-S062
  27. KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13
  28. Kim B, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.3
  29. Laws KR, 2016, WORLD J PSYCHIATR, V6, P54, DOI 10.5498/wjp.v6.i1.54
  30. Lind L, 2003, ATHEROSCLEROSIS, V169, P203, DOI 10.1016/S0021-9150(03)00012-1
  31. Marsland AL, 2015, BRAIN BEHAV IMMUN, V48, P195, DOI 10.1016/j.bbi.2015.03.015
  32. Matioli Maria Niures P.S., 2015, Dement. neuropsychol., V9, P96, DOI 10.1590/1980-57642015DN92000003
  33. MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
  34. McCrimmon RJ, 2012, LANCET, V379, P2291, DOI 10.1016/S0140-6736(12)60360-2
  35. Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2
  36. Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734
  37. Roriz JS, 2009, BBA-MOL BASIS DIS, V1792, P432, DOI 10.1016/j.bbadis.2008.12.003
  38. Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
  39. Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391
  40. Serrano-Pozo A, 2017, J ALZHEIMERS DIS, V59, P763, DOI 10.3233/JAD-170184
  41. Sperling R, 2014, NEURON, V84, P608, DOI 10.1016/j.neuron.2014.10.038
  42. Suemoto CK, 2015, ATHEROSCLEROSIS, V243, P510, DOI 10.1016/j.atherosclerosis.2015.10.008
  43. van Himbergen TM, 2012, ARCH NEUROL-CHICAGO, V69, P594, DOI 10.1001/archneurol.2011.670
  44. van Hooren SAH, 2007, AGING NEUROPSYCHOL C, V14, P40, DOI 10.1080/138255890969483
  45. Vina J, 2010, J ALZHEIMERS DIS, V20, pS527, DOI 10.3233/JAD-2010-100501
  46. WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016
  47. Wieser V, 2013, ARCH IMMUNOL THER EX, V61, P119, DOI 10.1007/s00005-012-0210-1
  48. Willette AA, 2015, ALZHEIMERS DEMENT, V11, P504, DOI 10.1016/j.jalz.2014.03.011
  49. 2014, EUR NEUROPSYCHOPHARM, V24, P1982, DOI 10.1016/J.EURONEURO.2014.03.002
  50. 2008, PSYCHOL AGING, V23, P608, DOI 10.1037/A0012838

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/66
Artigos e Materiais de Revistas Científicas - ODS/03